Author

N. J. Epsi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Ganesan· 2 shared B. K. Agan· 2 shared C. C. Broder· 2 shared C. J. Colombo· 2 shared D. A. Lindholm· 2 shared E. D. Laing· 2 shared M. P. Simons· 2 shared S. D. Pollett· 2 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Ganesan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

S. Lusvarghi, S. D. Pollett, S. N. Neerukonda, W. Wang, R. Wang, R. Vassell, N. J. Epsi, A. C. Fries, B. K. Agan, D. A. Lindholm, C. J. Colombo, R. Mody, E. C. Ewers, T. Lalani, A. Ganesan, , C. D. Weiss

A third dose of Pfizer/BioNTech vaccine significantly boosts Omicron neutralizing antibodies, while convalescent sera and therapeutic antibodies show variable and often low neutralization.

bioRxiv · Dec 22, 2021Microbiology

Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection

Z. Lu, E. D. Laing, J. Pena-Damata, K. Pohida, M. S. Tso, E. C. Samuels, N. J. Epsi, B. Dorjbal, C. Lake, S. A. Richard, R. C. Maves, D. A. Lindholm, J. Rozman, C. English, N. Huprikar, , A. M. Malloy

This study examines SARS-CoV-2-specific T cell responses 12-months post-infection, finding durable responses with higher frequencies in those with severe acute illness.

bioRxiv · Aug 11, 2021 · PreprintImmunology